Education
About Us
Working with TipRanks
Follow Us
Omega Diagnostics Group PLC (GB:CNSL)
LSE:CNSL
Top Page
Omega Diagnostics
(LSE:CNSL)
Select Model
Select Model
Rating:51Neutral
Price Target:
3.00p
▲(5.26% Upside)
Omega Diagnostics' overall stock score reflects a challenging financial and technical outlook. The most significant factor is the mixed financial performance, with profitability overshadowed by declining revenue and cash flow issues. Technical analysis indicates bearish momentum, further weighing down the score. The stock's valuation suggests it may be undervalued, providing a potential opportunity for value investors.
Omega Diagnostics (CNSL) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£6.78M
Dividend YieldN/A
Average Volume (3M)209.08K
Price to Earnings (P/E)4.3
Beta (1Y)0.95
Revenue Growth-14.77%
EPS GrowthN/A
CountryUK
Employees94
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.00
Shares Outstanding237,950,650
10 Day Avg. Volume259,853
30 Day Avg. Volume209,082
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.87
P/FCF Ratio-51.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£3.00Price Target Upside5.26% Upside
Rating ConsensusHold
Number of Analyst Covering0
Omega Diagnostics Business Overview & Revenue Model
Company DescriptionOmega Diagnostics (CNSL) is a biotechnology company focused on the development and commercialization of diagnostic tests for various medical conditions, particularly in the areas of allergy and infectious disease. The company operates primarily in the healthcare sector, leveraging its expertise in immunoassay technology to deliver high-quality, reliable diagnostic solutions. Core products include a range of diagnostic kits that are used by healthcare professionals to improve patient outcomes through accurate and timely testing.
How the Company Makes MoneyOmega Diagnostics generates revenue through the sale of its diagnostic products, which are marketed to hospitals, laboratories, and healthcare providers. The company has established key revenue streams from the distribution of its allergy testing kits and infectious disease diagnostics, which are often sold directly to healthcare facilities or through third-party distributors. Additionally, Omega may benefit from partnerships with other companies in the healthcare and diagnostics sectors, which can provide access to new markets and enhance its product offerings. The ongoing demand for accurate diagnostic testing in the healthcare industry, particularly in light of emerging health challenges, plays a significant role in sustaining and growing its earnings.
Omega Diagnostics Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.33M | 8.33M | 9.77M | 7.55M | 8.54M | 6.82M |
| Gross Profit | 5.00M | 5.00M | 6.05M | 3.17M | 4.75M | 4.00M |
| EBITDA | 2.20M | 2.20M | -73.00K | -2.65M | -382.00K | 418.00K |
| Net Income | 1.57M | 1.57M | -328.00K | -3.86M | -11.33M | -2.10M |
Balance Sheet | ||||||
| Total Assets | 13.80M | 13.80M | 13.89M | 14.40M | 17.84M | 29.55M |
| Cash, Cash Equivalents and Short-Term Investments | 4.87M | 4.87M | 5.44M | 5.12M | 1.60M | 5.83M |
| Total Debt | 349.00K | 349.00K | 148.00K | 74.00K | 370.00K | 2.84M |
| Total Liabilities | 2.39M | 2.39M | 4.21M | 4.45M | 6.02M | 6.16M |
| Stockholders Equity | 11.41M | 11.41M | 9.68M | 9.95M | 11.82M | 23.38M |
Cash Flow | ||||||
| Free Cash Flow | -142.00K | -142.00K | 548.00K | -3.31M | -4.71M | -5.24M |
| Operating Cash Flow | 83.00K | 83.00K | 607.00K | -3.15M | -3.23M | -2.42M |
| Investing Cash Flow | 2.12M | 2.12M | -2.51M | 5.18M | -493.00K | -2.83M |
| Financing Cash Flow | -251.00K | -251.00K | -265.00K | 1.49M | -502.00K | 11.07M |
Omega Diagnostics Technical Analysis
Negative
2.85
Price Trends
3.27
Negative
3.34
Negative
3.21
Negative
Market Momentum
-0.10
Positive
23.12
Positive
13.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CNSL, the sentiment is Negative. The current price of 2.85 is below the 20-day moving average (MA) of 3.05, below the 50-day MA of 3.27, and below the 200-day MA of 3.21, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 23.12 is Positive, neither overbought nor oversold. The STOCH value of 13.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CNSL.
Omega Diagnostics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | £173.00M | 28.08 | 19.61% | 3.84% | 10.32% | 1.25% | |
69 Neutral | £134.28M | 22.59 | 8.71% | 4.80% | -1.43% | 28.57% | |
53 Neutral | £7.14M | 1,150.00 | 0.08% | ― | 87.72% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £6.78M | 4.32 | 14.85% | ― | -14.77% | ― | |
49 Neutral | £4.38M | ― | -105.98% | ― | -25.05% | -5.74% |
* Healthcare Sector Average
GB:CNSL
Omega Diagnostics
2.85
-0.70
-19.72%
GB:RUA
RUA Life Sciences
11.50
-2.25
-16.36%
GB:EKF
EKF Diagnostics Holdings
30.20
-0.40
-1.31%
GB:FDBK
Feedback
10.75
-30.25
-73.78%
GB:CIZ
Cizzle Biotechnology Holdings PLC
1.40
-0.60
-30.00%
GB:TSTL
Tristel
362.50
-11.93
-3.19%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.